Discover 1,003 paid clinical trials in Saint Paul, Minnesota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,003
Active & Responsive
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
for
Chronic Granulomatous Disease (CGD)
Location: Saint Paul MN, Madison WI, Des Moines IA, Lincoln NE,
Sponsor: Ensoma
Sex: All
Age: 0+
Code: NCT06605378
Recruiting
Active & Responsive
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
for
Turner Syndrome, Short Stature Homeobox Gene Mutation,
Location: Saint Paul MN, Minneapolis MN, Cincinnati OH,
Sponsor: Ascendis Pharma A/S
Sex: All
Age: 2 - 17
Code: NCT07221851
Phase3, Recruiting
Active & Responsive
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: Maplewood MN, Rochester MN, Madison WI, Iowa City IA,
Sponsor: Bicara Therapeutics
Sex: All
Age: 18+
Code: NCT06788990
Phase2, Phase3, Recruiting
Active & Responsive
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
for
Cardiovascular Disease
Location: Maplewood MN, Minneapolis MN, Saint Louis Park MN,
Sponsor: Amgen
Sex: All
Age: 50 - 70+
Code: NCT07136012
Phase3, Recruiting
Active & Responsive
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
for
Chronic Obstructive Pulmonary Disease (COPD)
Location: Maplewood MN, Topeka KS, Indianapolis IN, Columbus OH,
Sponsor: Expedition Therapeutics, Inc
Sex: All
Age: 40 - 70+
Code: NCT07684820
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity